Fig. 1From: Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational researchTherapy, procedures and KRAS mutational status over the time course of the disease (5-FU = 5-fluouracile, Gy = Gray, PPPD = pylorus preserving pancreaticoduodenectomy)Back to article page